Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

Lancet Diabetes and Endocrinology,The - Tập 6 - Trang 370-381 - 2018
Bernhard Ludvik1, Juan P Frías2, Francisco J Tinahones3, Julio Wainstein4, Honghua Jiang5, Kenneth E Robertson5, Luis-Emilio García-Pérez5, D Bradley Woodward5, Zvonko Milicevic6
11st Medical Department and Karl Landsteiner Institute for Obesity and Metabolic Disorders, Rudolfstiftung Hospital, Vienna, Austria
2National Research Institute, Metro Medical Mall, Los Angeles, CA, USA
3Hospital Universitario Virgen de la Victoria (IBIMA), Málaga and CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Malaga, Spain
4Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
5Eli Lilly and Company, Corporate Center, Indianapolis, IN, USA
6Eli Lilly and Company, Vienna, Austria

Thông tin
Thông tin xuất bản

Lancet Diabetes and Endocrinology,The

Tập 6

370-381

Thông tin tác giả